Serina Therapeutics (SER) Cash & Equivalents (2017 - 2026)

Serina Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $3.1 million in Q4 2025.

• Quarterly Cash & Equivalents fell 16.78% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 16.78% YoY) and the FY2025 annual result came in at $3.1 million, down 16.78% from the prior year.
• Cash & Equivalents fell to $3.1 million in Q4 2025 per SER's latest filing, from $8.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $8.7 million in Q1 2024 and troughed at $261000.0 in Q2 2023.
• A 5-year average of $2.9 million and a median of $795000.0 in 2021 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 62.71% in 2023, then soared 3009.29% in 2024.
• Over 5 years, Cash & Equivalents stood at $584000.0 in 2021, then grew by 10.45% to $645000.0 in 2022, then soared by 1081.24% to $7.6 million in 2023, then plunged by 51.8% to $3.7 million in 2024, then dropped by 16.78% to $3.1 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.1 million, $8.6 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.